Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Wall Street suffered due to volatility in the first quarter of 2025. U.S. stock markets are likely to close the first quarter ...

Cardinal Health's CAH pharmaceutical segment has consistently demonstrated resilience and growth, driven by strong demand ...

JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions.

Meanwhile, Pulse Asia this month reported more than a third of registered voters in the country (37.9 percent) characterize Philippine politics as “magulo;” for almost a fifth of registered voters (17 ...

Cardinal Health (CAH) concluded the recent trading session at $132.75, signifying a -0.35% move from its prior day's close.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

The board of Cardinal Health, Inc. ( NYSE:CAH ) has announced that it will pay a dividend of $0.5056 per share on ...

Cardinal Health plans to release third-quarter financial results for its fiscal year 2025 on May 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a ...

Cardinal Health Inc. closed 0.34% below its 52-week high of $133.67, which the company reached on March 21st.

Cardinal Health outpaces S&P 500 with strong growth in specialty pharmaceuticals. Read why CAH stock has limited upside ...

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...